Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • Bitcoin USD

    63,944.29
    -865.37 (-1.34%)
     
  • CMC Crypto 200

    1,331.29
    -65.25 (-4.67%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • Dow

    38,239.66
    +153.86 (+0.40%)
     
  • Nasdaq

    15,927.90
    +316.14 (+2.03%)
     
  • Gold

    2,348.90
    +6.40 (+0.27%)
     
  • Crude Oil

    83.68
    +0.11 (+0.13%)
     
  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Is Eli Lilly or Bristol Myers Squibb the Better Value Stock to Buy Right Now?

Is Eli Lilly or Bristol Myers Squibb the Better Value Stock to Buy Right Now?

While growth stocks boomed in the era of easy money, value stocks have returned to form as the market's top performers in the current high interest rate environment. Now, value comes in many forms, such as a highly dependable dividend, an economically insensitive revenue stream, the quality of a company's management team, long-term growth drivers, and/or an attractive valuation. In the present risk-averse market, the most highly prized aspects of value stocks appear to be the dependability of a company's dividend, along with its ability to generate strong free cash flows regardless of the state of the broader economy.